Literature DB >> 23307209

Radiation-related cancer risk associated with surveillance imaging for metastasis from choroidal melanoma.

Joanne C Wen1, Victor Sai, Bradley R Straatsma, Tara A McCannel.   

Abstract

OBJECTIVE: To estimate the lifetime attributable risk of cancer associated with whole-body positron emission tomography (PET)/computed tomography (CT) and with CT of the chest, abdomen, and pelvis if performed at various frequencies and for different durations for surveillance of patients with primary choroidal or ciliary body melanoma for distant metastasis.
METHODS: Effective radiation doses for whole-body CT and for CT of the chest, abdomen, and pelvis were calculated using Monte Carlo simulation studies. The effective dose of the PET scan was estimated by multiplying fludeoxyglucose F18 radioactivity with dose coefficients. Lifetime attributable risks of cancer were calculated using the approach described in the Biological Effects of Ionizing Radiation VII report.
RESULTS: For a 50-year-old patient, an annual CT of the chest, abdomen, and pelvis for 10 years carries an estimated lifetime attributable risk of cancer of 0.9% for male patients and 1.3% for female patients, whereas an annual PET/CT each year for 10 years carries an estimated lifetime attributable risk of cancer of 1.6% for male patients and 1.9% for female patients. Lifetime risk was found to be higher in younger, female patients. The lifetime attributable risk of cancer was estimated to be as high as 7.9% for a 20-year-old female patient receiving a PET/CT scan every 6 months for 10 years.
CONCLUSIONS: Aggressive surveillance protocols incorporating CT scanning or PET/CT scanning for detection of metastasis from primary choroidal or ciliary body melanoma appear to confer a significant substantial risk of a secondary malignant tumor in patients who do not succumb to metastatic melanoma within the first few posttreatment years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307209     DOI: 10.1001/jamaophthalmol.2013.564

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  7 in total

Review 1.  Latest developments in the biology and management of uveal melanoma.

Authors:  Sapna P Patel
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Cumulative radiation exposure and estimated lifetime cancer risk in multiple-injury adult patients undergoing repeated or multiple CTs.

Authors:  S Kritsaneepaiboon; A Jutiyon; A Krisanachinda
Journal:  Eur J Trauma Emerg Surg       Date:  2016-03-24       Impact factor: 3.693

Review 3.  Uveal melanoma: From diagnosis to treatment and the science in between.

Authors:  Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

4.  The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation.

Authors:  Armin R Afshar; Michael Deiner; Grant Allen; Bertil E Damato
Journal:  Ocul Oncol Pathol       Date:  2018-02-08

5.  Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI.

Authors:  Johannes Grueneisen; Lino Morris Sawicki; Benedikt Michael Schaarschmidt; Saravanabavaan Suntharalingam; Sara von der Ropp; Axel Wetter; Verena Ruhlmann; Harald H Quick; Michael Forsting; Lale Umutlu
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

Review 6.  Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Authors:  Benjamin A Krantz; Nikita Dave; Kimberly M Komatsubara; Brian P Marr; Richard D Carvajal
Journal:  Clin Ophthalmol       Date:  2017-01-31

7.  Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors.

Authors:  Vasilios P Papastefanou; Shahriar Islam; Teresa Szyszko; Marianne Grantham; Mandeep S Sagoo; Victoria M L Cohen
Journal:  Br J Ophthalmol       Date:  2014-08-01       Impact factor: 4.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.